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DObjectives: Pulmonary hypertension (PH) is an indicator of a poor prognosis in patients with dilated cardiomy-
opathy. Few studies have investigated the prognostic role of PH in patients undergoing restrictive mitral
annuloplasty (RMA) for severe functional mitral regurgitation secondary to advanced cardiomyopathy.
Methods: A total of 46 patients undergoing RMA were classified into 3 groups on the basis of the Doppler-
derived systolic pulmonary artery pressure (PAP) at baseline. Of the 46 patients, 19 had a systolic PAP less
than 40 mm Hg (mild PH group), 17 had a systolic PAP of 40 to 60 mm Hg (moderate PH group), and 10
had a systolic PAP greater than 60 mm Hg (severe PH group).
Results: Postoperative cardiac catheterization showed that the RMA procedure resulted in a significant reduc-
tion of the left ventricular (LV) preload and improvements in LV systolic function in all 3 groups, along with the
relief of symptoms. During the follow-up period (mean, 36  19 months), cardiac death occurred in 6 patients,
readmission because of heart failure in 3, and fatal arrhythmia in 1. The rate of freedom from these cardiac events
at 3 years was 93%  7%, 88%  8%, and 56%  17% in the mild, moderate, and severe PH groups
(P<.001). Serial echocardiography showed that significant LV reverse remodeling occurred in 89%, 71%,
and 25% of the mild, moderate, and severe PH groups, respectively. Multivariate Cox regression analysis iden-
tified severe PH (systolic PAP>60 mm Hg) as a significant predictor of adverse cardiac events, as well as LV
remodeling after RMA.
Conclusions: Noninvasive assessment of preoperative PH has a prognostic value in patients undergoing RMA
for severe functional mitral regurgitation secondary to advanced cardiomyopathy. (J Thorac Cardiovasc Surg
2011;142:783-92)It is well known that pulmonary hypertension (PH) is an
indicator of a poor prognosis in patients with dilated cardio-
myopathy and functional mitral regurgitation (MR),1 as
well as in heart transplant recipients.2 However, whether
PH has the same prognostic value in patients who have
undergone surgery for functional MR complicated by
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The Journal of Thoracic and CaSince Bolling and colleagues3 first reported the feasibility
of surgery for uncontrollable severe MR in patients with
end-stage cardiomyopathy, restrictive mitral annuloplasty
(RMA) has become the preferred surgical treatment of this
condition. Several factors have been shown to be predictors
of poor outcome after RMA.4-8 However, few investigations
have assessed the influence of PH on symptomatic
improvements, left ventricular (LV) function, or survival
after RMA in patients with advanced cardiomyopathy.
In the present study, we investigated whether PH has
a prognostic value in patients undergoing RMA for func-
tional MR. In addition, we determined which parameters
might function as predictors of postoperative outcome and
reverse LV remodeling in those patients, with a focus on
preoperative PH.
MATERIALS AND METHODS
Patients
We examined the records of 65 consecutive patients who had undergone
RMA for functional MR at our institution from March 2004 to December
2009. Of those, 46 patients were chosen as study subjects, according to the
following inclusion criteria: (1) chronic heart failure with New York Heart
Association (NYHA) functional class III or IV and a history of at least 1
hospitalization; (2) advanced LV remodeling, defined as a LV ejectionrdiovascular Surgery c Volume 142, Number 4 783
Abbreviations and Acronyms
BNP ¼ brain natriuretic peptide
LV ¼ left ventricular
LVEDD ¼ left ventricular end-diastolic
dimension
LVEF ¼ left ventricular ejection fraction
MR ¼ mitral regurgitation
NYHA ¼ New York Heart Association
PAP ¼ pulmonary artery pressure
PH ¼ pulmonary hypertension
PVR ¼ pulmonary vascular resistance
RMA ¼ restrictive mitral annuloplasty
TR ¼ tricuspid regurgitation
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Dfraction (LVEF) of less than 40% and LV end-systolic volume index
greater than 60 ml/m2, as shown by left ventriculography; and (3) severe
MR caused by restrictive leaflet motion secondary to global LV dilatation.
Patients with a lesser degree of LV remodeling and ischemic MR second-
ary to a regional LV deformity due to inferior/posterior myocardial infarc-
tion were excluded from the present study. The patients with recent
myocardial infarction (< 3 months), organic MR, rheumatic mitral dis-
ease, or a known noncardiac cause of PH were not included in the present
study.
To determine whether the degree of preoperative PH was associated
with the postoperative outcome, the patients were classified into 3 groups
according to the Doppler-derived systolic pulmonary artery pressure (PAP)
at baseline. Of the 46 patients, 19 had a systolic PAP of less than 40 mmHg
(mild PH group), 17 had a systolic PAP of 40 to 60 mm Hg (moderate PH
group), and 10 had a systolic PAP greater than 60 mm Hg (severe PH
group).
The clinical characteristics and surgical data are listed in Table 1. No
significant differences were found in gender, body surface area, NYHA
functional class, or prevalence of complications among the 3 groups. The
patients in the severe PH group had had a longer duration of heart failure
than those in the other groups, although theywere younger than the patients
in the moderate PH group.
The related institutional ethics committees approved the present study
and waived the need for individual consent for the retrospective analysis.
Each patient provided written informed consent for the procedure before
surgery.Echocardiographic Measurements and Calculations
Two-dimensional and Doppler transthoracic echocardiography were
performed at baseline, at 1 month after surgery (mean, 28  5 days), and
annually thereafter. The preoperative (baseline) and postoperative echocar-
diographic examinations at 1 month after surgery were performed within 1
day of cardiac catheterization. Transesophageal echocardiography was also
performed within 1 week before surgery to confirm the severity and precise
mechanism of MR in all patients. All echocardiographic studies were per-
formed using commercially available 3.75-MHz transducers (Toshiba,
Tokyo, Japan, and Hewlett-Packard Sonos) by the same echocardiographic
expert examiner (S.F.), who was unaware of the clinical status of the
patients.LV Function and Left Atrial Dimensions
The LVend-diastolic dimension (LVEDD), LVend-systolic dimension,
and left atrial dimension was determined from 2-dimensional echocardio-784 The Journal of Thoracic and Cardiovascular Surggraphic images in the parasternal long-axis views. The LVEF was
calculated using Simpson’s method with 2 apical views.
Doppler-Derived Systolic PAP
The systolic PAPwas calculated by adding the systolic pressure gradient
across the tricuspid valve derived from the tricuspid regurgitation (TR) to
the estimated right atrial pressure.9,10 The tricuspid regurgitant signal was
recorded by continuous-wave Doppler echocardiography, and its maximal
velocity was measured. Using the simplified Bernoulli equation, the
pressure gradient across the tricuspid valve was calculated. The right atrial
pressurewas estimated using the dimension of the inferior vena cava and the
response to changes in respiration.11 In the present patients, a tricuspid re-
gurgitant signal was detected in all patients during the baseline examination
and in the great majority of patients during the follow-up examinations.
Mitral and Tricuspid Valve Measurements
The severity of MR and TR was graded semiquantitatively from the
color flow Doppler data. In our routine assessment, MR severity was char-
acterized as none (0), trivial (1þ), mild (2þ), moderate (3þ), or severe (4þ),
depending on how far beyond the mitral valve the regurgitation extended
into the left atrium. The tenting height was measured between the line con-
necting the annular hinge points and the leaflet coaptation point, and the
coaptation length was measured directly. The area of the mitral valve ori-
fice was determined by direct planimetry or using the pressure half-time
method, and the mean transmitral diastolic gradient was calculated using
the Bernoulli equation determined from continuous-wave Doppler echo-
cardiography.
Cardiac Catheterization and Hemodynamic
Measurements
Cardiac catheterization was performed before and 1month after surgery
to measure the following routine cardiac hemodynamic parameters: LV
end-diastolic volume index, LV end-systolic volume index, LV systolic
pressure, LV end-diastolic pressure, pulmonary capillary wedge pressure,
systolic and mean PAP, transmitral diastolic pressure gradient (pulmonary
capillary wedge pressure minus the LVend-diastolic pressure), right atrial
pressure, systemic vascular resistance ([mean arterial pressure minus right
atrial pressure] multiplied by 80 and divided by the cardiac output), and
pulmonary vascular resistance (PVR) ([mean PAP minus pulmonary capil-
lary wedge pressure] multiplied by 80 and divided by the cardiac output).
Our catheterization technique has been previously described.12
Surgical Procedures
A median sternotomy was performed under a mild hypothermic cardio-
pulmonary bypass, with intermittent cold blood cardioplegia. Mitral valve
surgery was performed through a trans-septal superior approach.
Carpentier-Edwards physio rings (Carpentier Ring, Edwards Lifesciences,
Irvine, Calif) were used for all RMA procedures. The ring size was deter-
mined after careful measurement of the intercommissural distance and the
height of the anterior leaflet and then downsizing by 2 to 3 sizes. No other
adjunct procedures were performed on the valve itself. No significant dif-
ferences were found in regard to the surgical procedures among the groups,
including the size of the mitral annulus ring implanted and frequency of the
concomitant procedures (Table 1).
Clinical Follow-up
Clinical follow-up examinations were completed for the 43 operative
survivors, with a mean duration of 36  19 months (range, 5–77 months).
After surgery, the patients were treated with standard heart failure medica-
tions, including angiotensin-converting enzyme inhibitors or angiotensin-II
receptor blockers, b-blockers, and diuretics. Every 6 to 12 months, they
were assessed in our department and by their primary cardiologist. The
functional status was assessed according to the NYHA criteria forery c October 2011
TABLE 1. Clinical characteristics and surgical data
Parameter All (n ¼ 46) Mild (n ¼ 19) Moderate (n ¼ 17) Severe (n ¼ 10) P Value
Age (y) 64  8 62  9 68  6* 60  7 .02
Men (%) 35 (76) 13 (68) 14 (82) 8 (80) NS
Body surface area (m2) 1.7  0.2 1.6  0.2 1.7  0.2 1.6  0.2 NS
NYHA functional class 3.2  0.4 3.2  0.4 3.1  0.3 3.2  0.4 NS
Duration of HF (mo) 25  15 18  9* 24  14* 39  15 < .01
Ischemic etiology (%) 32 (70) 14 (74) 12 (71) 6 (60) NS
Hypertension 30 (65) 13 (68) 12 (71) 5 (50) NS
Diabetes 17 (37) 8 (42) 6 (35) 3 (30) NS
Hyperlipidemia 20 (43) 10 (0) 6 (35) 4 (40) NS
COPD 7 (15) 1 (5) 3 (18) 3 (30) NS
Chronic renal disease 16 (35) 7 (37) 3 (18) 6 (60) NS
Peripheral vascular disease 6 (13) 0 (0) 3 (18) 3 (30) NS
Cerebrovascular accident 14 (30) 4 (21) 6 (35) 4 (40) NS
Atrial fibrillation 21 (46) 9 (47) 8 (47) 4 (40) NS
Previous CABG 1 (2) 0 (0) 0 (0) 1 (10) NS
Previous PCI 13 (28) 5 (26) 5 (29) 3 (30) NS
b-Blockers 33 (72) 17 (89) 11 (65) 5 (50) NS
ACE inhibitors 9 (20) 3 (16) 4 (24) 2 (20) NS
ARB 17 (37) 9 (47) 7 (41) 1 (10) NS
Nitrate 12 (26) 6 (32) 3 (18) 3 (30) NS
Diuretics 34 (74) 11 (58) 15 (82) 8 (80) NS
Surgical data
CPB (min) 240  71 222  43 252  69 252  109 NS
ACC (min) 133  43 130  40 147  42 114  43 NS
Physio ring (mm)
24 37 (80) 15 (79) 15 (82) 7 (70) NS
26 9 (20) 4 (21) 2 (12) 3 (30) NS
Concomitant procedure
CABG 26 (57) 11 (58) 10 (59) 5 (50) NS
TAP 43 (93) 17 (89) 16 (94) 10 (100) NS
Modified maze 21 (46) 9 (47) 8 (47) 4 (40) NS
NYHA, New York Heart Association; HF, heart failure; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary
intervention; ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker; CPB, cardiopulmonary bypass; ACC, aortic crossclamp; TAP, tricuspid annuloplasty.
*P<.05 versus severe PH.
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Dsymptoms of heart failure and serum brain natriuretic peptide (BNP) level.
A retrospective review of the medical records of these patients was per-
formed for the preoperative and postoperative data, and the current infor-
mation was obtained by interviewing the patient or the referring
cardiologist. The postoperative adverse cardiac events included cardiac
death, myocardial infarction, endocarditis, thromboembolism, reoperation
for recurrent MR, readmission for heart failure, and fatal arrhythmia.
Statistical Analysis
The values for continuous variables are expressed as the mean  stan-
dard deviation. The Kruskal-Wallis and chi-square tests were used to com-
pare the pre- and postoperative values among the 3 groups. The functional
and echocardiographic variables over time were compared using repeated
measures analysis of variance, followed by a Bonferroni test for individual
significant differences. Univariate analysis of the predictors of adverse
cardiac events was performed using a Cox proportional hazard model
(see Appendix). The factors with P<.1 were then entered appropriately
into a multivariate model. The results are summarized as hazard ratios
and 95% confidence intervals. Stepwise logistic regression analysis was
performed to identify predictors for failure of reverse LV remodeling
(see Appendix). Kaplan-Meier and log-rank analyses were performed to
compare survival and the freedom from adverse cardiac events. Correla-
tions between the Doppler-derived and catheter-measured systolic PAPThe Journal of Thoracic and Cawere tested using linear correlation analysis. A Bland-Altman analysis
was used to further determine the agreement between the 2 modalities by
calculating the bias (mean difference) and 95% limits of agreement ( 2
standard deviation).13 P < .05 was considered statistically significant.
The statistical analyses were performed using JMP, version 7.0 (SAS
Institute, Cary, NC).RESULTS
Survival
In the mild PH group, 1 early noncardiac death and 1 late
fatal arrhythmia occurred. In the moderate PH group, 2 late
cardiac deaths occurred. In the severe PH group, 2 early car-
diac deaths, 2 late cardiac deaths, and 3 late readmissions
because of heart failure occurred. None of the patients re-
quired reoperation forMR recurrence or endocarditis or pre-
sented with myocardial infarction or cerebrovascular or
thromboembolic events during the follow-up period. The
actuarial survival rate free from all deaths at 3 years was
95% 5%, 88% 8%, and 70% 15% in themild, mod-
erate, and severe PH groups, respectively (P ¼ .09;rdiovascular Surgery c Volume 142, Number 4 785
FIGURE 1. Actuarial survival rates. Circles, triangles, and squares
indicate mild, moderate and severe groups, respectively. PH, Pulmonary
hypertension. Numbers at bottom indicate patients at risk at each interval.
FIGURE 2. Freedom from adverse cardiac events. Circles, triangles, and
squares indicate mild, moderate, and severe groups, respectively. PH, Pul-
monary hypertension. Numbers at bottom indicate patients at risk at each
interval.
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cardiac events at 3 years were 93%  7%, 88%  8%,
and 56%  17% (P<.001; Figure 2). The severity of pre-
operative PH was significantly associated with overall sur-
vival and the freedom from adverse cardiac events.
Acute Hemodynamic Changes After RMA
Preoperatively, all patients showed impairment of sys-
temic and pulmonary hemodynamic conditions, the severity
of which increased with the severity of the PH (Table 2,
Figure 3). The systolic and mean PAP and PVR in the severe
PH group were significantly greater than those in the other 2
groups.
From baseline to 1 month after surgery, the patients in the
mild PH group showed good functional improvement, but
those in the severe PH group showed less improvement.
The patients in the moderate PH group showed improve-
ment that was intermediate between that of the mild and se-
vere PH groups. The LV volumes significantly decreased,
and the LVEF improved in all 3 groups, although patients
in the severe PH group showed less improvement in those
parameters than in the other 2 groups. The LV systolic pres-
sures did not change; however, the LV end-diastolic pres-
sure decreased significantly in all groups.
In the patients with mild and moderate PH, the cardiac in-
dex increased significantly, the systemic vascular resistance
decreased, and the systolic and mean PAP and PVR re-
mained unchanged. In contrast, in the severe PH group,
the cardiac index and systemic vascular resistance remained
unchanged, and the systolic and mean PAP and the PVR
significantly decreased. In the severe PH group, both
systolic and mean PAP and PVR significantly decreased;
Importantly, in patients with severe PH, the systolic PAP786 The Journal of Thoracic and Cardiovascular Surgand PVR at 1 month after surgery were significantly greater
than those in the mild PH group and remained substantially
abnormal, suggesting the persistence of abnormal pulmo-
nary hemodynamics.Serial Echocardiographic Examinations
LV dimensions and function and left atrial dimensions.
In the mild and moderate groups, the LVEDD, left ventric-
ular end-systolic dimension, and left atrial dimension had
decreased significantly and the LVEF had improved at 1
month after surgery (Table 3, Figure 4). Also, these im-
provements (reverse remodeling) persisted during the
follow-up period. In the severe PH group, the LV dimen-
sions remained unchanged at 1 month after surgery and
were significantly greater than the other 2 groups. In addi-
tion, the severe PH group had lower LVEF values than the
mild andmoderate PH groups at all follow-up examinations.
Doppler-derived systolic PAP. In the mild and moderate
PH groups, the mean systolic PAP at 1 month after surgery
had remained or returned to a normal range in most patients.
Those values had stabilized within the normal range during
the follow-up period, along with an improvement in MR. In
contrast, the mean systolic PAP in the severe PH group had
decreased at 1 month after surgery; however, the values had
never returned to a normal range, regardless of significant
improvement in MR. The systolic PAP in the severe PH
group had gradually worsened for a period of years, in con-
trast to the LV systolic function and LV dimension.
Mitral valve performance and measurements. Serial ex-
aminations showed significant improvements in MR in all
groups, with optimal mitral valve geometry in terms ofery c October 2011
TABLE 2. Acute hemodynamic changes
Variable
All Mild Moderate Severe
Baseline
(n ¼ 46)
Discharge
(n ¼ 33)
Baseline
(n ¼ 19)
Discharge
(n ¼ 13)
Baseline
(n ¼ 17)
Discharge
(n ¼ 14)
Baseline
(n ¼ 10)
Discharge
(n ¼ 6)
LVEDVI (mL/m2) 140  38 110  35* 129  29 105  22* 144  45 106  42* 155  35 133  41*
LVESVI (mL/m2) 104  34 59  29* 94  25 53  17* 105  40 54  28* 120  33 85  40*
LVEF (%) 26  7 37  12* 27  8 39  10* 28  7 38  13* 23  6 32  16*
LVSP (mm Hg) 116  22 120  15 114  19 120  14 120  20 121  15 111  29 118  20
LVEDP (mm Hg) 20  8 12  4* 17  8y 10  3* 20  5 14  4* 26  8 14  5*
PCWP (mm Hg) 20  8 15  5* 16  8y 13  4 20  6 16  4 27  8 17  7
Systolic PAP (mm Hg) 44  15 35  8* 34  10y 31  7y 43  10y 38  8 59  16 39  10*
Mean PAP (mm Hg) 29  10 23  5* 22  7y 20  4y 29  7y 25  5 40  10 26  5*
RAP (mm Hg) 8.2  4.5 8.9  3.0 6.7  3.8 8.0  2.9 7.9  4.8 9.7  2.7 10.0  4.2 9.0  4.0
CI (L/min/m2) 2.6  0.6 3.0  0.7* 2.6  0.5 3.1  0.7*y 2.7  0.6 3.0  0.7*y 2.2  0.6 2.2  0.4
TMPG (mm Hg) 0.4  6.4 2.5  3.1 0.1  6.6 2.8  3.1 0.2  7.0 2.1  2.9 1.4  5.5 2.7  3.7
SVR (dynes $ s $ cm5) 1520  380 1320  420* 1590  340 1310  310* 1490  470 1240  290* 1470  310 1520  740
PVR (dynes $ s $ cm5) 171  90 137  54 127  62y 123  44y 162  48y 143  63 243  122 147  53*
LVEDVI, Left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVEF, left ventricular ejection fraction; PCWP, pulmonary capillary
wedge pressure; PAP, pulmonary artery pressure; RAP, right atrial pressure; CI, cardiac index; TMPG, transmitral pressure gradient; SVR, systemic vascular resistance; PVR,
pulmonary vascular resistance. *P<.05 versus variables at baseline in each group. yP<.05 versus severe PH group at each point.
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Da decreased tenting height and adequate coaptation length.
No significant differences were found postoperatively in
the changes in MR grade, TR grade, coaptation length, tent-
ing height, mitral valve orifice area, or mean transmitral
pressure gradient among the 3 study groups.FIGURE 3. Acute hemodynamic changes after restrictive mitral annuloplasty. *
hypertension (PH) group. LVSP, Left ventricular systolic pressure; PCWP, pulmo
index; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance.
respectively.
The Journal of Thoracic and CaSymptoms and Serum BNP Levels
The NYHA functional improvements and changes in se-
rum BNP levels were not significantly associated with the
preoperative severity of PH (Figure 5). The patients in the
severe PH group tended to show less improvement. InP<.05 versus value at baseline, yP<.05 versus value for severe pulmonary
nary capillary wedge pressure; PAP, pulmonary artery pressure;CI, cardiac
Circles, triangles, and squares indicate mild, moderate, and severe groups,
rdiovascular Surgery c Volume 142, Number 4 787
TABLE 3. Serial echocardiographic and functional variables
Variable Baseline 1 mo 1 y 2 y P Value
LVEDD (mm)
All 66  6 60  7* 60  8* 59  8* < .01
Mild PH group 66  6 58  6*,y 58  9* 57  9* < .01
Moderate PH group 65  6 58  7*,y 58  5* 56  4* < .01
Severe PH group 69  6 67  6 66  8 64  10 NS
LVESD (mm)
All 55  7 48  10* 45  10* 44  12* < .01
Mild PH group 54  7y 45  8*,y 42  9* 40  11* < .01
Moderate PH group 53  7y 46  10*,y 43  10* 41  6* < .01
Severe PH group 61  6 58  7 52  11 52  13 NS
LVEF (%)
All 32  5 39  8* 44  7* 45  7* < .01
Mild PH group 34  4y 42  5*,y 46  7*y 49  6*,y < .01
Moderate PH group 33  6y 40  10*,y 45  5*y 45  5*,y < .01
Severe PH group 29  4 31  6 37  9* 39  8* .02
LA dimension (mm)
All 51  7 45  6* 48  5* 48  5* < .01
Mild PH group 49  6 44  6*,y 48  5 47  5 .03
Moderate PH group 51  6 45  3* 48  5 49  4 < .01
Severe PH group 52  9 50  7 50  6 49  8 NS
Systolic PAP (mm Hg)
All 47  15 36  8* 38  9* 37  13* < .01
Mild PH group 33  4y 33  6 32  9 29  9 NS
Moderate PH group 48  6y 36  7* 36  8* 36  10* .02
Severe PH group 70  9 42  8* 50  11* 54  17 .01
MR grade
All 3.6  0.5 0.9  0.7* 0.9  0.7* 1.0  0.7* < .01
Mild PH group 3.6  0.5 0.8  0.4* 0.8  0.7* 0.8  0.6* < .01
Moderate PH group 3.6  0.5 0.9  0.7* 0.8  0.6* 1.0  0.0* < .01
Severe PH group 3.8  0.5 1.3  1.2* 1.0  0.9* 1.3  1.0* .02
TR grade
All 2.3  1.1 0.9  0.6* 0.9  0.6* 1.0  0.6* < .01
Mild PH group 2.3  1.2 0.8  0.7* 0.8  0.6* 1.0  0.0* < .01
Moderate PH group 2.2  1.0 0.8  0.4* 0.8  0.4* 1.2  0.8* .02
Severe PH group 2.5  1.3 1.1  0.6* 1.3  0.7* 1.2  0.4* .03
Tenting height (mm)
All 7.9  2.4 4.2  1.9* 3.8  0.9* 4.0  1.4* < .01
Mild PH group 6.7  2.3 4.7  2.2* 4.0  1.1* 3.6  0.4* < .01
Moderate PH group 8.0  2.0 3.7  1.2* 3.6  0.7* 4.3  2.0* < .01
Severe PH group 10.1  1.7 4.1  2.3* 3.8  0.8* 4.2  0.3* < .01
Coaptation length (mm)
All 4.1  1.5 8.0  2.4* 8.2  1.1* 7.9  1.1* < .01
Mild PH group 4.4  1.7 7.4  1.8* 8.1  1.4* 8.0  1.3* < .01
Moderate PH group 4.2  1.5 8.7  3.0* 8.2  1.0* 7.9  1.0* < .01
Severe PH group 3.0  0.7 7.9  2.0* 8.3  1.3* 7.7  1.3* < .01
Effective orifice area (cm2)
All 2.6  0.3 2.6  0.4 2.5  0.4 NS
Mild PH group 2.6  0.3 2.6  0.3 2.5  0.3 NS
Moderate PH group 2.6  0.4 2.6  0.3 2.5  0.3 NS
Severe PH group 2.6  0.4 2.7  0.4 2.6  0.4 NS
(Continued)
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functional class improved significantly, and the improve-
ment persisted during the follow-up period, along with re-
duced serum BNP levels.788 The Journal of Thoracic and Cardiovascular SurgPrediction for Reverse LV Remodeling
When substantial reverse LV remodeling was defined as
a 10% reduction in the LVEDD, LV reverse remodeling
was seen in 16 (89%) of 18 patients with mild PH, 12ery c October 2011
TABLE 3. Continued
Variable Baseline 1 mo 1 y 2 y P Value
TMPG (mm Hg)
All 4.2  1.5 4.3  1.6 4.7  2.3 NS
Mild PH group 4.7  1.6 4.6  1.3 4.9  2.0 NS
Moderate PH group 3.7  1.3 3.9  1.3 4.7  2.1 NS
Severe PH group 4.4  1.4 4.5  2.6 4.5  3.4 NS
LVEDD, left ventricular end-diastolic dimension; PH, pulmonary hypertension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; LA, left
atrial; PAP, pulmonary artery pressure; MR, mitral regurgitation; TR, tricuspid regurgitation; TMPG, transmitral pressure gradient. *P<.05 versus values at baseline in each
group. yP<.05 versus severe PH group at each point.
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with severe PH (P ¼ NS) at their most recent examination
(Table 4). Univariate analysis identified LV systolic dys-
function (P ¼ .022), a longer duration of heart failure
(P ¼ .01), and severe PH (systolic PAP> 60 mm Hg;
P ¼ .004) as important predictors of failure of reverse
LV remodeling. In addition, multivariate analysis identi-
fied severe PH as a significant predictor.
Prediction of Postoperative Adverse Cardiac Events
Finally, the potential predictors of postoperative adverse
cardiac eventswere examinedusing aCoxproportional hazard
model (Table 5). Univariate analysis identified preoperative
LV systolic dysfunction (P ¼ .04), a longer duration of heart
failure (P ¼ .021), and severe PH (systolic PAP> 60 mm
Hg; P¼ .002) as important predictors. In addition, multivari-
ate analysis identified severe PH as a significant predictor.
DISCUSSION
The results of the present study suggest that PH in pa-
tients with advanced cardiomyopathy undergoing RMA isFIGURE 4. Serial echocardiographic changes after restrictive mitral annulop
PH group. LVEDD, Left ventricular end-diastolic dimension; LVEF, left vent
PAP, pulmonary artery pressure; PH, pulmonary hypertension.
The Journal of Thoracic and Casignificantly associated with adverse short-term clinical
outcome in terms of overall survival, adverse cardiac events
(including cardiac death, readmission for heart failure, and
fatal arrhythmia), improvements in NYHA functional class
and serum BNP levels, acute hemodynamic changes, and
serial echocardiographic changes in LV dimensions and
function. Our findings have also demonstrated that severe
PH (systolic PAP>60 mm Hg) was an important hemody-
namic predictor of adverse cardiac events, as well as failure
of LV reverse remodeling after surgical treatment for
functional MR and LV dysfunction.
In previous studies, clinical variables such as advanced
age, preoperative hemodialysis and diabetes,4 larger LV
dimensions,5,6 and nonischemic etiology and a longer
duration of heart failure7 were shown to be significantly
associated with poor outcomes after RMA. In addition,
the more sophisticated echocardiographic parameters of
LV systolic and diastolic dysfunction such as LVEDD
(> 65 mm) and left ventricular end-systolic dimension
(>51 mm),8 myocardial performance index, systolic sphe-
ricity, wall motion score index,14,15 restrictive LV fillinglasty. *P<.05 versus value at baseline, yP<.05 versus value for severe
ricular ejection fraction; LVESD, left ventricular end-systolic dimension;
rdiovascular Surgery c Volume 142, Number 4 789
FIGURE 5. Serial changes in New York Heart Association (NYHA) functional class and serum brain natriuretic peptide (BNP) level. *P<.05 versus value
at baseline. Gray, white, and black bars indicate mild, moderate, and severe groups, respectively.
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Dpattern and mitral deceleration time (<140 ms)16 have been
reported to be strong predictors of poor outcome or a lack of
LV reverse remodeling after RMA. These parameters have
also been shown to predict late MR recurrence after mitral
annuloplasty. The present results have suggested that the
PH level is a strong predictor of outcome after RMA and
also provided additional important prognostic information
that is complementary to the classic echocardiographic pa-
rameters of LV systolic and diastolic dysfunction.
The etiologies of PH in patients with cardiomyopathy are
heterogeneous, and the determinants of its reversibility after
an annuloplasty procedure have not been fully clarified. Clas-
sically, PH inpatientswith cardiomyopathyhas been attributed
to elevatedLVfilling pressures, reactive pulmonary arterial va-
soconstriction, pulmonary vascular remodeling, or all three17;
it has also been associated with functional MR.18 The in-
creased PAPassociatedwith early-stage cardiomyopathy prin-TABLE 4. Predictors of failure in left ventricular reverse remodeling
Variable
Univariate Multivariate
P
Value
Odds
ratio
95%
CI
P
Value
Odds
ratio
95%
CI
Age NS
Ischemic etiology NS
Duration of HF .01 1.1 1.02–1.15 NS
History of VT NS
LVEDD (continuous) NS
LVEDD (>65 mm) NS
LVESD (continuous) NS
LVESD (>50 mm) NS
LA dimension (mm) NS
LVEF (%) .02 0.8 0.70–0.97 NS
Severe PH* .004 25.7 4.3–155 .03 10.0 1.3–75
MR grade NS
TR grade NS
CI, Confidence interval; HF, heart failure; VT, ventricular tachycardia; LVEDD, left
ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension;
LA , left atrial; LVEF, left ventricular ejection fraction; PH, pulmonary hypertension;
MR, mitral regurgitation; TR, tricuspid regurgitation. *Systolic PAP>60 mm Hg.
790 The Journal of Thoracic and Cardiovascular Surgcipally results fromelevatedLVfilling pressures.18 In addition,
longstanding elevation of LV filling pressures can lead to sev-
eral histologic changes in pulmonary circulation, including
medial hypertrophy of arterioles, intimal fibroproliferation,
and arterialization of the pulmonary veins.17 These changes
have also been associated with neurohumoral activation, in
particular of endothelin-1,19,20 a potent vasoconstrictor that
is markedly increased in patients with advanced heart failure.
These pathophysiologic changes are dependent on the
chronicity and severity of PH and can initially be reversible,
although the conditions can eventually become irreversible.17
The changes in pulmonary hemodynamics seen in the
present severe PH group were consistent with this sequence
of PH progression. The patients in the severe PH group had
had a longer duration of heart failure and greater PVR
values before surgery. Furthermore, the mean PVR value
in this group remained considerably elevated at 1 monthTABLE 5. Predictors of adverse cardiac events
Variable
Univariate Multivariate
P
Value
Hazard
ratio
95%
CI
P
Value
Hazard
ratio
95%
CI
Age NS
Ischemic etiology NS
Duration of HF .02 1.05 1.01–1.10 NS
History of VT NS
LVEDD (continuous) NS
LVEDD (>65 mm) NS
LVESD (continuous) NS
LVESD (>50 mm) NS
LA dimension (mm) NS
LVEF (%) .04 0.89 0.79–0.96 NS
Severe PH* .002 9.1 2.3–35 .04 6.9 1.1–44
MR grade NS
TR grade NS
CI, Confidence interval; HF, heart failure; VT, ventricular tachycardia; LVEDD, left
ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension;
LA, left atrial; LVEF, left ventricular ejection fraction; PH, pulmonary hypertension;
MR, mitral regurgitation; TR, tricuspid regurgitation. *Systolic PAP>60 mm Hg.
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Dafter surgery. The elevated PAP levels (>40 mm Hg) per-
sisted at all follow-up examinations, suggesting the pres-
ence of irreversible pulmonary vascular disease. In
contrast, the moderate PH group showed a decline in the
systolic PAP without a change in the lowered PVR at dis-
charge. Also, the lower PAP values were maintained until
the latest follow-up examination, suggesting that PH was
reversible in these patients. Thus, our findings emphasize
the importance of assessing PVR and the degree of pulmo-
nary vascular remodeling. In addition, our results might
support the use of surgery for patients with medically un-
controllable severe functional MR before the pulmonary
vascular disease becomes irreversible.
The degree of PH is not only related to the severity of LV
systolic dysfunction, but is also strongly associated with
the LV diastolic dysfunction (ie, a greater level of PH has
been associated with a shorter mitral deceleration time).18
Gelsomino and colleagues21 reported that the Doppler-
derived mitral deceleration time was prognostic for LV re-
verse remodeling after undersized mitral annuloplasty. Our
results are not necessarily inconsistent with those of previ-
ous studies, because a strong correlation between the
Doppler-derived systolic PAP and mitral deceleration
time has been reported.18 Also, the prevalence of a restric-
tive filling pattern has been inversely related to the LVEF.
PH has also been significantly associated with right ven-
tricular function and right heart hemodynamics. In con-
trast, the right ventricular EF will correlate with the
systolic PAP and is an independent predictor of survival
in patients with moderate heart failure.22 This association
between PH and right ventricular dysfunction could ex-
plain why the level of PH provides additional prognostic
information beyond the LV systolic and diastolic dysfunc-
tion variables.
It remains controversial whether patients with end-stage
heart failure and functional MR can benefit from RMA.23-25
In our study, patients with mild and moderate PH (Doppler-
derived PAP<60 mm Hg) showed functional improvement
and satisfactory long-term survival. In contrast, those with
severe PH (systolic PAP>60 mm Hg) had relatively poor
outcomes. Our results have shown that RMAwas able to im-
prove hemodynamics and symptoms in these patients. How-
ever, the lack of an untreated control group did not allow us
to investigate the survival benefit conferred by RMA for
patients with significant MR and severe LV dysfunction.
Additional studies of late mortality after RMA in similar
patient populations are needed.
Study Limitations
The main limitations of the present study were its retro-
spective nature and the small number of subjects. The
inclusion of patients with ischemic and nonischemic cardio-
myopathy and those who had undergone concomitant coro-
nary artery bypass grafting, tricuspid annuloplasty, andThe Journal of Thoracic and Caa maze procedure for atrial fibrillation might have influ-
enced the results. However, these concomitant procedures
are usually required in a population of very sick patients
who present with similar clinical and pathophysiologic sta-
tus despite the etiology of LV dysfunction. To minimize the
potential bias related to patient selection, our study popula-
tion consisted only of patients with advanced nonischemic
or ischemic cardiomyopathy owing to anterior infarction
and functional MR. Patients with less LV remodeling and
ischemic MR secondary to predominant inferior/posterior
infarction, who have often been included in previous stud-
ies,6-8,15,16,21,24 were excluded from our study. Therefore,
our results would not be applicable to patients with
previous inferior or lateral infarction.
During the late follow-up examinations, systolic PAPwas
determined noninvasively using Doppler echocardiography
and not measured by catheterization. This noninvasive
method has been fully validated and currently represents
a standard approach for PH determination. In the present
study, we confirmed that systolic PAP estimated using
Doppler echocardiography correlated significantly with
the nonsimultaneously catheter-derived systolic PAP
(r ¼ .833, P< .001). Moreover, Bland-Altman analysis
showed that the 2 modalities had good agreement in the
measurements of systolic PAP, although it was slightly
overestimated using Doppler echocardiography (mean
bias 1.5  8.4 mm Hg).
The medical treatments administered could have also
affected our findings. However, the preoperative medical
therapies were continued without significant modifications
after surgical intervention. In particular, the use and
dosage of angiotensin-converting enzyme inhibitors and
angiotensin-II receptor blockers were not changed; thus,
their influence on LV remodeling and pulmonary vascular
remodeling in our patients was considered to be negligible.CONCLUSIONS
Noninvasive assessment of systolic PAP was found to be
an excellent prognostic tool for patients who underwent
RMA for functional MR secondary to advanced cardiomy-
opathy. Additional studies are needed to define the mecha-
nism of PH and its postoperative reversibility in patients
with cardiomyopathy to establish new treatment strategies.
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